A FAST score is a noninvasive liver test that identifies people with a serious, progressive form of fatty liver disease. It stands for FibroScan-AST, and it combines three measurements to assess whether someone has fatty liver disease that’s actively causing inflammation and scarring. The score ranges from 0 to 1, with higher numbers indicating a greater likelihood of significant liver damage. If your doctor mentioned a FAST score, it almost certainly came up in the context of evaluating your liver health.
You may also know the acronym FAST from stroke awareness campaigns (Face, Arms, Speech, Time). That’s a completely different tool. This article covers the liver-related FAST score, which is a relatively new diagnostic calculation used in hepatology.
What the FAST Score Measures
The FAST score was designed to detect a specific and dangerous combination: fatty liver disease with significant inflammation and meaningful scarring (fibrosis). In medical terms, it identifies nonalcoholic steatohepatitis, or NASH, that has progressed beyond the early stages. Not everyone with a fatty liver develops this kind of damage, so the FAST score helps sort out who needs closer attention from who can be monitored more conservatively.
It does this by pulling together three pieces of information, each capturing a different dimension of liver health:
- Liver stiffness measurement (LSM): Captured during a FibroScan, this tells your doctor how much scarring (fibrosis) is present. Stiffer liver tissue means more scarring.
- Controlled attenuation parameter (CAP): Also from the FibroScan, this measures how much fat has accumulated in your liver.
- AST (aspartate aminotransferase): A liver enzyme measured through a standard blood draw. Elevated AST signals ongoing liver inflammation or damage.
By combining fat accumulation, scarring, and active inflammation into a single number, the FAST score gives a more complete picture than any one test alone. A FibroScan by itself can tell you about stiffness or fat, but it doesn’t directly capture inflammation. A blood test showing elevated AST doesn’t tell you about scarring. The FAST score bridges those gaps.
How a FAST Score Is Calculated
You don’t need to calculate your own FAST score. It’s generated using a mathematical formula that your doctor or the FibroScan software applies after collecting the three inputs: liver stiffness, liver fat measurement, and your AST blood level. The formula produces a number between 0 and 1.
Getting the score requires two things: a FibroScan exam (a painless, ultrasound-based procedure that takes about 10 minutes) and a blood test. There are no needles involved in the FibroScan itself. A technician places a probe against your right side, and it sends gentle vibrations through your liver to measure stiffness and fat content. The AST level comes from routine bloodwork that may already be part of your liver workup.
What Your Score Means
The FAST score uses two key thresholds to sort patients into three groups. These cutoffs were established in the original study published in The Lancet Gastroenterology & Hepatology and have been validated across multiple populations:
- Below 0.35 (rule-out zone): A score in this range makes it unlikely that you have NASH with significant fibrosis. Most people in this category can avoid a liver biopsy and be monitored over time.
- Between 0.35 and 0.67 (gray zone): The result is inconclusive. Your doctor may recommend additional testing, closer follow-up, or possibly a liver biopsy depending on your overall clinical picture.
- Above 0.67 (rule-in zone): A score this high strongly suggests NASH with significant inflammation and scarring. A liver biopsy or further evaluation is typically the next step to confirm the diagnosis and plan treatment.
These thresholds are designed to be conservative. The lower cutoff prioritizes not missing anyone who truly has significant disease, while the upper cutoff prioritizes not sending people for unnecessary biopsies.
How Accurate Is It
The FAST score consistently achieves an AUROC of around 0.80 to 0.81 across different study populations. In practical terms, that means it correctly distinguishes patients with significant NASH from those without it about 80% of the time. That’s a strong result for a noninvasive screening tool, though it’s not perfect, which is why scores in the gray zone still require clinical judgment.
When compared head-to-head with other noninvasive scoring systems, the FAST score comes out ahead. The FIB-4 index, another common liver fibrosis calculator, scored an AUROC of 0.73 in the same validation study. The NAFLD fibrosis score (NFS) came in at 0.67, and the APRI score at 0.74. The FAST score’s advantage comes from incorporating liver fat and stiffness data from the FibroScan rather than relying solely on blood markers.
Interestingly, the score performs somewhat differently across populations. Validation studies found higher accuracy in non-white patients compared to white patients (AUROC of 0.91 versus 0.78), and in people with lower BMI. In participants with a BMI under 25, the AUROC reached 0.94. This doesn’t mean the test is unreliable in other groups, but it does suggest accuracy can vary depending on body composition and other individual factors.
Why the FAST Score Matters
Fatty liver disease is extremely common, affecting roughly a quarter of the global population. Most people with simple fatty liver never develop serious problems. The challenge is identifying the smaller subset whose disease is progressing toward NASH with significant fibrosis, because that’s the group at risk for cirrhosis, liver failure, and liver cancer.
Before tools like the FAST score existed, the only reliable way to make that distinction was a liver biopsy, an invasive procedure that involves inserting a needle into the liver to extract a tissue sample. Biopsies carry a small risk of complications and aren’t practical for screening large numbers of patients. The FAST score was developed specifically to reduce unnecessary biopsies by identifying, without any invasive procedure, which patients are most likely to have progressed disease and which can safely skip the biopsy.
The score has also become important in clinical trials for new fatty liver treatments. Pharmaceutical companies use FAST score thresholds to screen potential participants and identify patients whose disease is active enough to benefit from experimental therapies. This has made the score a standard part of the research pipeline for NASH drug development, which in turn means more doctors are using it in routine clinical care.
Limitations to Keep in Mind
The FAST score requires access to a FibroScan device, which not every clinic or hospital has. If your doctor doesn’t have one on-site, you may need a referral to a hepatology center or imaging facility that does.
FibroScan readings can also be less reliable in certain situations. Obesity can make it harder to get accurate measurements, and recent eating can temporarily affect liver stiffness readings, which is why you’re typically asked to fast before the exam. Active inflammation from causes other than fatty liver disease (like a viral hepatitis flare) can also inflate the stiffness measurement and skew the score.
A FAST score is a screening tool, not a definitive diagnosis. A high score strongly suggests significant disease, but a liver biopsy remains the gold standard for confirming NASH and staging exactly how much damage has occurred. The score’s real value is in helping your doctor decide whether that biopsy is warranted in the first place.